Mushtaque Ahmed, MD
Internal Medicine · Humble, TXNPI 1689843518
Payments from drug & device makers
What this record shows
This record is dominated by grants: $7,400 of the $9,136 with a category attached, or 81.0%. Medtronic accounts for 81.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $7,400 and has fallen 96.5% since, to $256 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $125.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Novo Nordisk$207
- Exact Sciences$174
- Lilly USA, LLC$161
- Boston Scientific$159
- Ancora Heart, Inc.$134
- plus $835 from 23 others
What the payments were for
- Grants$7,40081%
- Food & beverage$1,73619%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AccuCinch$134
- WATCHMAN FLX$116
How this compares
$9,136 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $84,577 |
| JardianceEmpagliflozin | 39 | $46,381 |
| EliquisApixaban | 29 | $35,577 |
| JanuviaSitagliptin Phosphate | 30 | $28,409 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $22,293 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 22 | $21,594 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $18,287 |
| TrulicityDulaglutide | 11 | $17,950 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $16,571 |
| FarxigaDapagliflozin Propanediol | 15 | $16,316 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $6,858 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,400 |
| Atorvastatin Calcium | 421 | $4,095 |
| Rosuvastatin Calcium | 218 | $3,594 |
| Sildenafil Citrate | 35 | $3,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $207 | $84,57768 claims |
| MerckJanuvia, Janumet Xr | $18 | $50,00352 claims |
| PfizerEliquis | $101 | $35,57729 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $50 | $28,69331 claims |
| Lilly USA, LLCTrulicity | $161 | $17,95011 claims |
| AstraZenecaFarxiga | $39 | $16,31615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Humble
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.